1. Pharmaceutical cGMPs for the 21st Century – a risk-based approach, Final report, Department of Health and Human Services, U.S. Food and Drug Administration, September 2004.
2. A quality by design approach to impurity method development for atomoxetine hydrochloride (LY139603)
3. ICH Harmonized Tripartite Guideline, Pharmaceutical Development, Q8(R2), August 2009.
4. ICH Harmonized Tripartite Guideline, Development and Manufacture of Drug Substances (Chemical entities and biotechnological/biological entities), Q11, May 2012.
5. Guidelines from the International Conference on Harmonisation (ICH)